Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan ...

for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA ® (olutasidenib) for the treatment of relapsed or ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their ...

WHEELING, W.Va. — Govenor Jim Justice joined West Virginia Tourism Secretary Chelsea Ruby and other officials in Wheeling to present a $4.4 million AML Economic Revitalization grant in support ...

A new study has revealed insights into the behaviour of platelet factor XIII-A (FXIII-A), a major cytoplasmic protein, during platelet activation. Researchers sought to understand how FXIII-A is ...

Acute myeloid leukemia (AML) five-year survival rate is 27.6% ... As their numbers increase, leukemia cells prevent the growth of healthy red blood cells and platelets. There are many forms of this ...

A Maitland, Florida bank has agreed to revamp its money laundering oversight program after being cited by the Office of the Comptroller of the Currency. Axiom Bank entered into a formal agreement with ...

1,2 GPS is also being evaluated in the phase 3 REGAL trial (NCT04229979) against investigator’s choice of best available maintenance therapy for the treatment of adult patients with AML in second or ...